EQL takes back Potassium Chloride rights in Denmark and Norway

On November 24, 2017, EQL announced that a license agreement has been entered into with a leading generic company for the license of EQL's product Potassium Chloride in Denmark, Norway and Finland. The agreement ran for three years and the reason for the out-licensing of Potassium Chloride was primarily that EQL at that time was not willing to tie up as much capital in stock as a launch of Potassium Chloride in these markets required. The license agreement was structured so that EQL received part of the profit from the sales of the product.

When the agreement expired earlier this year, EQL chose to extend the agreement for Finland, but take back the rights for Denmark and Norway. This means that Potassium Chloride EQL Pharma 750mg prolonged-release tablets for the treatment of potassium deficiency, which EQL already offers in Sweden, will start to be sold in Denmark during the current quarter. Sales in Norway have not taken place during the license period and EQL is now evaluating that market for launch of the product.

The market in Denmark has a turnover of approx. 77mDKK per year and in addition to EQL has two other active suppliers.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.